Showing 1 - 2 results of 2 for search 'Jodi Layton', query time: 0.02s Refine Results
  1. 1
    Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort

    Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort by Pedro Barata, Whitley Hatton, Arpita Desai, Vadim Koshkin, Ellen Jaeger, Charlotte Manogue, Patrick Cotogno, Malcolm Light, Brian Lewis, Jodi Layton, Oliver Sartor, Arnab Basu, Deepak Kilari, Hamid Emamekhoo, Mehmet A. Bilen

    Published 2020-10-01
    Get full text
    Article
  2. 2
    Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer

    Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer by Marcus Moses, MS, Alex Niu, MD, Michael B. Lilly, MD, Andrew W. Hahn, MD, Roberto Nussenzveig, PhD, Elisa Ledet, PhD, Charlotte Manogue, MPH, Patrick Cotogno, MSPH, Brian Lewis, MD, MPH, Jodi Layton, MD, Neeraj Agarwal, MD, Oliver Sartor, MD, Pedro C. Barata, MD, MSc

    Published 2020-01-01
    Get full text
    Article

Search Tools: